Traxion Sab De Cv Ord Shs GRPOF

Tetra Bio-Pharma Signs a Definitive Distribution Agreement

[monarka]

Tetra Bio-Pharma Signs a Definitive Distribution Agreement with DanCann Pharma to Monetize Its Dronabinol and Botanical Product Portfolios Medicines Agency (EMA), DanCann Pharma will handle the exclusive sales and distribution in the Nordics and Germany for Reduvo Adversa and QIXLEEF, a botanical cannabinoid-derived medicine, as well as Tetra's medicinal cannabis product ENJOUCA. The Agreement encompasses a sum of upfront and milestone payments of up to $1,5M CAD, and expected cumulative royalties in excess of $46M CAD on DanCann's cumulative sales for Reduvo Adversa, QIXLEEF and ENJOUCA from 2021 to 2028. According to Guy Chamberland, CEO at Tetra Bio-Pharma: "I am glad that we were able to sign this definitive agreement with DanCann Pharma. Both organizations strongly believe that cannabinoid-derived medicines will help improve the quality of life of patients suffering from pain and chemotherapy induced nausea and vomiting (CINV). We look forward to working with DanCann Pharma in the Nordic Countries and Germany. Both organizations set the bar very high when it comes to delivering impactful therapeutic value medicines to patients. This partnership will strengthen our business model and demonstrates that Tetra keeps delivering on our commitment to shareholders to monetize our assets and transitioning from a pre-revenue biopharma company to an in-revenue biopharma company."